The North-East Moroccan physicians' management of menopause: Prescription vs. nonprescription of hormonal treatment

Sara Esseffar, Abdelmajid Moumen, Samia Rkha, Mohamed Loukid

Abstract

This study examined the management of North-East Moroccan physicians of menopause. The poll was carried out on a representative sample of physicians in the Nador region. The sample included gynecologists and general practitioner physicians in both public and private medical sectors. The survey contained focused and open-ended questions on the good knowledge or not of physicians about menopause, their patient population, their prescribing practices, their perceptions, and the different medical approaches to managing the symptoms of menopause. Among the general practitioners interviewed, only 16% of physicians are very knowledgeable about the management of menopause and only 3 physicians have followed continuous training. The others have mainly acquired their information from the internet, medical journals, and scientific magazines. Only one-third of physicians interviewed prescribe menopausal hormonal treatment in this region. The treatment is mainly prescribed to cope with hot flashes (97.1%) and menstrual cycle disruption (85.7%). Others are in favor of non-hormonal treatments and advise women to change their bad daily habits to relieve symptoms. In this region of Morocco, hormonal treatment for menopause is not very common and the majority of general practitioners are not familiar with menopause. (Afr J Reprod Health 2022; 26[6]:116-124).

Full Text:

PDF

References

Kaufert PA. Myth and the menopause. Soc. Health &Illness 1982:4(2): 141-166.

Davis ME and Boynton MW. Indications, clinical use and toxicity of 4'4' dihydroxy-diethyl stilbene. J. clin. Endocr. 1941;1, 339-345.

Pratt JP. Sex functions in man. In Sex and Internal Secretions (Edited by Allen E., Danforth C. H. and Doisy E. A.), Williams & Wilkins, Baltimore, Md., 1939: 1263-1334.

Frank RT. Treatment of disorders of the menopause. Bull. N.Y. Acad. Med. 1941;17, 856-863.

Derman RJ, Danwood MY and Stone S, Quality of life during sequential hormone replacement therapy - a placebo-controlled study. Int. J.Fertil. Menopausal Stud.1995;40, 73-78.

Skarsgard C, Berg G, Ekblad S, Wiklund I and Hammar M. Effects of estrogen therapy on wellbeing in postmenopausal women without vasomotor complaints. Maturitas2000; 36, 123-130.

Wiklund I, Berg G, Hammar M, Karlberg J, Lindgren R and Sandin K. Long-term effect of transdermal therapy on aspects of quality of life in postmenopausal women. Maturitas, 1992;14, 225-236.

Wiklund I, Karlberg J and Mattsson L-A. Quality of life of postmenopausal women on a regimen of transdermal estradiol therapy: a double-blind placebo-controlled study. Am. J. Obstet. Gynecol., 1993;168, 824-830.

Henderson BE, Paganini-Hill A and Ross RK. Decreased mortality in users of estrogen replacement therapy. Arch Intern Med, 1991;151, 75-78.

Paganini-Hill A and Henderson VW. Estrogen replacement therapy and risk of Alzheimer disease. Arch Intern Med, 1996;156, 2213-2217.

Cauley JA, Seeley DG, Ensrud K, Ettinger B, Black D and Cummings SR. Estrogen replacement therapy and fractures in older women. Study of Osteoporotic Fractures Research Group. Ann Intern Med, 1995;122, 9-16.

Ettinger B, Golditch IM and Friedman G. Gynecologic consequences of long-term, unopposed estrogen replacement therapy. Maturitas, 1988;10, 271-282.

Ettinger B, Friedman GD, Bush T and Quesenberry CR Jr. Reduced mortality associated with long-term postmenopausal estrogen therapy. ObstetGynecol, 1996;87, 6-12.

Ettinger B, Pressman A and Van Gessel A. Low-dosage esterified estrogens opposed by progestin at 6-month intervals. ObstetGynecol, 2001;98, 205-211.

Grodstein F, Stamfer MJ, Coldiz GA, Willet WC, Manson JE, Joffe M, Rosner B, Fuchs C, Hankinson SE, Hunter DJ, Hennekens CH and Speizer FE. Postmenopausal hormone therapy and mortality. N Engl J Med, 1997;336, 1769-1775.

Grodstein F, Stamfer MJ, Falkeborn M, Naessen T and Persson I. Postmenopausal hormone therapy and risk of cardiovascular disease and hip fracture in a cohort of Swedish women. Epidemiology,1999;10, 476-480.

Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, Ernster VL and Cummings SR. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med, 1992:117, 1016-1037.

Girdler SS, O'Briant C, Steege J, Grewen K and Light KC. A comparison of the effect of estrogen with or without progesterone on mood and physical symptoms in postmenopausal women. J Women Health Gend Based Med, 1999;8, 637-646.

Bixo M, Andersson A, Winblad B, Purdy RH and Bäckström T. Progesterone, 5alpha-pregnane3,20-dione and 3alpha-hydroxy-5alpha-pregnane-20-one in specific regions of the human female brain in different endocrine states. Brain Res, 1997;764, 173-178.

Skarsgard C, Björs E, Nedstrand E, Wyon Y and Hammar M. Do women's premenstrual symptoms and their mothers' climacteric history predispose to their own vasomotor symptoms? Menopause, 1996;3, 133-139.

Hammarbäck S, Bäckström T, Holst J, von Schoultz B and Lyrenäs S. Cyclical mood changes as in the premenstrual tension syndrome during sequential estrogen-progestagen postmenopausal replacement therapy. ActaObstetGynecolScand, 1985;64, 393-397.

Hammarbäck S, Ekholm UB and Bäckström T. Spontaneous anovulation causing disappearance of cyclical symptoms in women with the premenstrual syndrome. ActaEndocrinol, 1991;125, 132-137.

Hlatky MA, Boothroyd D, Vittinghoff E, Sharp P and Whooley MA. Quality-of-life and depressive symptoms in postmenopausal women after receiving hormone therapy: results from the Heart and Estrogen/progestin Replacement Study (HERS) trial. JAMA, 2002;287, 591-597.

Hays J, Ockene JK, Btunner RL, Kotchen JM, Manson JE and Patterson RE. Effects of estrogen plus progestin on health-related quality of life. N Engl J Med, 2003;348, 1839-1854.

Million Women Study Collaborators Breast Cancer and hormone replacement therapy in the Million Women Study. Lancet, 2003;362, 419-427.

Grady D, Gebretsadik T, Kerlikowske K, Ernster V and Petitti D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. ObstetGynecol, 1995;85, 304-313.

Crandall CJ, Hovey KM, Andrews CA, Chlebowski RT, Stefanick ML, Lane DS, Shifren J, Chen C, Kaunitz AM, Cauley JA and Manson JE. Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women’s Health Initiative Observational Study. Menopause, 2018; 25(1), 11–20.

Pavlidou E, Pirtea P and Streuli I, Traitement hormonal de la ménopause en 2016, Rev. Med Suisse, 2016 ;12, 1805-1810.

Mintziori G, Lambrinoudaki I, Goulis DG, Ceausu I, Depypere H, Erel CT, Pérez-Lopez FR, Schenck-Gustafsson K, Simoncini T, Tremollieres F and Rees M. EMAS Position statement : Non-hormonal management of menopausal vasomotor symptoms, Maturitas, 2015 ;81, 410-413.

Taku K, Kronenberg MKF, Kurze MS and Messina M. Extracted or synthesized soybean isoflavones reduce menopausal hot flash frequency and severity: systematic review and meta-analysis of randomized controlled trials, Menopause, 2012;19, 776-790.

Thompson EA, Montgomery A, Douglas D, Reilly D and Pilot A. randomized, double-blinded, placebo-controlled trial of individualized homeopathy for symptomsof estrogen withdrawal in breast-cancer survivors. J. Altern. Complement Med, 2005;11, 13–20.

Daley A, Stokes-Lampard H, Thomas A and MacArthur C. Exercise for vasomotor menopausal symptoms, Cochrane Database Syst. Rev.2014;11, CD006108.

Stefanopoulou E and Hunter MS. Telephone-guided self-help cognitive behavioral therapy for menopausal symptoms, Maturitas, 2014;77, 73-77.

Woods NF, Mitchell ES and Schnall JG. Effects of mind-body therapies on symptom clusters during the menopausal transition. Climateric, 2014;17, 10-22.

Stojanovska L, Apostolopoulos V, Polman R and Borkoles E. To exercise, or not to exercise, during menopause and beyond, Maturitas, 2014;77, 318-323.

Löwy I and Gaudillière J-P. CONTROVERSES SUR LE TRAITEMENT HORMONAL DE LA MÉNOPAUSE, La Découverte « Mouvements », 2004 ;2 (32), 32-39.

Bermejo MJ and Ruiz Pérez I. Physicians and the prescription of hormone replacement therapy in

Spain, Health Policy, 2005;73, 1, 58-65.

Pinkerton JV, Aguirre FS, Blake J, Cosman F, Hodis HN, Hoffstetter S, Kaunitz AM, Kingsberg SH, Maki PM, Manson JE, Marchbanks P, McClung MR, Nachtigall LE, Nelson LM, Pace DT, Reid RL, Sarrel PM, Shifren JL, Stuenkel CA and Utian WH. The 2017 hormone therapy position statement of the North American Menopause Society, Menopause.2017;24 (7), 728-753.

Academic Committee of the Korean Society of Menopause, Lee SR, Cho MK, Cho YJ, Chun S, Hong S-H, Hwang KR, Jeon J-H, Joo JK, Kim SK, Lee DO, Lee D-Y, Lee ES, Song JY, Yi KW, Yun BH, Shin J-H, Chae HD and Kim T, The 2020 Menopausal Hormone Thearapy Guidelines, Journal of Menopausal Medecine, 2020;26, 69-98.

Obermeyer CM, Schulien M, Hajji N and Azelmat M. Menopause in Morocco: symptomatolgy and medical management, Maturitas, 2002;41, 87-95.

Annuaire-statistique-du-Maroc-version-PDF_2018

Sievert LL, Saliba M, Reher D, Sahel A, Hoyer D, Deeb M and Obermeyer CM. The medical management of menopause: A four-country comparison care in urban areas, Maturitas, 2008;59, 7-21.

Nalet P. Le traitement hormonal de la ménopause (THM) chez les jeunes médecins généralistes de Gironde : connaissances, attitudes et pratiques, Thèse pour l’obtention du diplôme d’état du doctorat en médecine, Université de Bordeaux 2015.

Morch LS, Lidegaard O and Keiding N. The influence of hormone therapies on colon and rectal cancer, Eur. J. Epidemiol., 2016;31: 5,481-489.

Prentice RL, Pettinger M and Beresford SAA. Colorectal cancer in relation to postmenopausal estrogen and estrogen plus progestin in the Women’s Health Initiative clinical trial and observational study. Cancer EpidemiolBiomark Prev. 2009; 18(5) :1531– 1537.

Nilsen ST, Fredriksen T, Iversen OE and Moen MH. Attitude to and practice of Norwegian gynecologists concerning hormone replacement therapy in climacteric. Tidsskrift Norske Laegeforening, 1998;118:19, 2940-2943.

Greendale G, Carlson K and Schiff I. Estrogen and progestin therapy to prevent osteoporosis: attitudes and practices of general internists and gynecologists. J General Int Med., 1996;11(14), 197-203.

Hunskar S, Hannestad YS, Back B and Matheson I. Attitudes of Norwegian general practitioners to prescription of estrogens. Tidsskrift Norske Laegeforening, 1994;114(8), 2095-2098.

Huston S, Sleath B and Ruben HR. Physician Gender and Hormone Replacement Therapy Discussion. Journal of Women’s Health& Gender-Based Medicine. 2001;10(3), Mary Ann Liebert, Inc.

Refbacks

  • There are currently no refbacks.